ReviewCambridge prisms. Extinction2025
Intergenerational justice, the impending sixth mass extinction, reproduction and advanced biotechnologies, and humanity's future.
Review in Cambridge prisms. Extinction, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intergenerational justice is the core principle supporting the legacy of benefit toward future generations, including the perpetuation of species and their genetic diversity, as a key component of biospheric sustainability. Thirty percent of Earth's terrestrial habitats are now undergoing protection, biodiversity hotspots are being targeted, and there is increasing community awareness and engagement in conservation. However, the impending sixth mass extinction threatens to drive many species to extinction in the wild, irrespective of these interventions. Earth's biosphere is now undergoing terraforming through ecosystem destruction and modification, urbanization, and agriculture. Therefore, transformative cultural, political, and economic incentives are needed to maximize the legacy of the Earth's biodiversity and biospheric sustainability toward future generations. Reproduction and advanced biotechnologies can perpetuate species and their genetic diversity while also contributing to human and animal health and agricultural production. Advanced reproduction biotechnologies, including genetic engineering and synthetic biology, provide a new horizon for biospheric management, through the de-extinction of ancient species, restoring recently lost species, and maintaining the genetic diversity of extant species through wildlife biobanking. More extensive and inclusive conservation breeding programs and wildlife biobanking resources/facilities are desperately needed to perpetuate more than 3,000 Critically Endangered terrestrial/freshwater species; a goal fully attainable for amphibians and smaller fishes through global inclusion of stakeholders including private caregivers, plausible for freshwater mussels and crayfish, in development for reptiles and birds, and applicable for many mammals. As this capacity develops, many otherwise neglected species that are losing their natural habitat can be perpetuated solely in biobanks, thus enabling the more efficient utilization of resources toward meaningful field conservation primarily through habitat protection. The full potential of reproduction and advanced biotechnologies includes the development of artificial wombs to address the human population crisis and to avoid surrogacy mismatching during species restoration or de-extinction. The use of advanced reproduction biotechnologies for direct human benefit, for species management, and for biospheric sustainability, are subject to evolving ethical and legal frameworks, particularly regarding genetic engineering, transhumanism, and the de-extinction of ancient species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.